Report Detail
Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis
- RnM2895563 |
- 12 March, 2020 |
- Global |
- 112 Pages |
- IQ4I Research & Consultancy |
- Other
“Nonalcoholicsteatohepatitis(NASH)PipelineAnalysis”givescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.Thereportcoversallthedrugsbeingdevelopedinvariousphases(Discovery,Preclinical&Clinicaldevelopment).Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNA-basedtherapeutics,butexcludesOff-label,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitis(NASH)Drugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministration(FDA)andthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliver-destroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceutical&biotechcompanies.AssomeofthecandidatesarenearingkeyR&Dmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead’sacquisitionofPhenexFXRprogram&Boehringer’sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnon-invasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNA-basedtherapies&Recombinantproteins.ThesemodalitiesmayprovideAnti-fibrosis,Anti-inflammatoryandmetabolicbenefits.
REPORT DESCRIPTION INTRODUCTION
• Causes & Symptoms
• Diagnosis
• Unmet needs
• Current therapies
HOT TARGETS, MECHANISMS & THERAPIES
• Novel Disease mechanisms & therapies
• Leading & hot targets of NASH
• Novel targets of NASH
• NASH biomarkers • Genes involved in NASH
MARKET DATA
• Forecasting model
• Market dynamics
• Market sizing
• NASH Deals
PIPELINE ANALYSIS
• Development stage
• Leading players
• Therapeutic segmentation
• Target analysis
• Innovative approaches
Small molecules
• Pipeline
• Competitive landscape Large molecules
• Competitive landscape RNA-BASED THERAPY
• Pipeline
• Competitive landscape RECOMBINANT PROTEINS
• Pipeline
• Competitive landscape ANTIBODIES
• Pipeline
• Competitive landscape LARGE MOLECULES (UNSPECIFIED)
• Pipeline
OTHER MOLECULES
• Pipeline
NASH DRUG ANALYSIS BASED ON MECHANISM
MAJOR PLAYERS
• Company Profiles
• Overview, Pipeline & Deals
REFERENCE
Summary:
Get latest Market Research Reports on Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis. Industry analysis & Market Report on Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis is a syndicated market report, published as Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis. It is complete Research Study and Industry Analysis of Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
